Results 151 to 160 of about 281,298 (260)

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

DNA methylation profiling enables subclassification of mucinous ovarian carcinoma and distinguishes it from extraovarian mucinous metastases. [PDF]

Cell Rep Med
Calina TG, Grafenhorst E, Schallenberg S, Möbs M, Daenekas B, Sabo AA, Chen B, Koch I, Janik T, Churchman M, Gourley C, Christie EL, Vasilescu C, Herlea V, Schmitt WD, Leopold N, Heitz F, Vlaski A, Tolkach Y, Bremmer F, Klauschen F, Büttner R, Ströbel P, Burandt E, Sauter G, Heppner FL, Taube ET, Sehouli J, Braicu IE, Euskirchen P, Horst D, Gorringe KL, Capper D, Dragomir MP.   +33 more
europepmc   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Survival Impact of Bevacizumab According to Chemotherapy Response Score in Advanced High-Grade Serous Ovarian Carcinoma Treated with Neoadjuvant Chemotherapy. [PDF]

Cancers (Basel)
Ege HV, Tuncer H, Akgör U, Gultekin M, Tuncer ZS, Basaran D.   +5 more
europepmc   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub, Armin Sepp, Amin Rostami‐Hodjegan, Brahim Achour   +3 more
wiley   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Spontaneous Tumor Lysis Syndrome Revealing Advanced Ovarian Carcinoma: From Oncologic Emergency to Complete Pathologic Response. [PDF]

Cureus
Rosado Rivera JM, Rivera Caro AP, Guerrero-Gonzalez M, Ocana-Vazquez E, Horta Vargas C, Carrero Quiñones M, Merle S.   +6 more
europepmc   +1 more source

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

Biotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady, Nicholas Donohue, Alexandra Bogdanovic, Sharon Davin, Brian Glennon, Niall Barron, C. Mark Smales   +6 more
wiley   +1 more source

CAAP1 suppresses tumor growth and metastasis via interacting with EIF3I in high-grade serous ovarian carcinoma. [PDF]

Am J Cancer Res
Wang C, Liang L, Kuang L, Liu S, Qian W, Zhang C.   +5 more
europepmc   +1 more source

Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma. [PDF]

Br J Cancer
Li X, Janik T, Möbs M, Florian S, Schmitt WD, Dzakulic A, Sehouli J, Horst D, Dubois FPB, Braicu EI, Dragomir MP.   +10 more
europepmc   +1 more source